Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Good Life Advisors LLC

Good Life Advisors LLC decreased its position in Bristol-Myers Squibb (NYSE:BMY) by 3.7% during the fourth quarter, Holdings Channel reports. The firm owned 16,792 shares of the biopharmaceutical company’s stock after selling 647 shares during the quarter. Good Life Advisors LLC’s holdings in Bristol-Myers Squibb were worth $862,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of BMY. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at about $25,000. True Wealth Design LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $26,000. Milestone Investment Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the third quarter worth $27,000. Coppell Advisory Solutions LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter valued at about $28,000. Finally, Blue Bell Private Wealth Management LLC lifted its stake in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.8 %

BMY traded up $0.98 during trading on Thursday, hitting $54.23. 13,446,705 shares of the company’s stock traded hands, compared to its average volume of 16,859,297. The company’s 50 day simple moving average is $50.79 and its two-hundred day simple moving average is $52.44. The stock has a market capitalization of $109.91 billion, a price-to-earnings ratio of 14.08, a PEG ratio of 1.59 and a beta of 0.38. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $71.07.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same quarter last year, the business posted $1.82 earnings per share. The firm’s revenue was up .6% on a year-over-year basis. Analysts predict that Bristol-Myers Squibb will post 6.61 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.43%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Bristol-Myers Squibb announced that its board has authorized a stock repurchase plan on Thursday, December 7th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to reacquire up to 2.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BMY. Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company cut their target price on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 6th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.12.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.